Trial Protocol ID USOR 21320_ONC-003

Trial Description

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib (Acclaim-1 Trial)

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • John Wallmark, M.D.
Early Development Program

Disease Types


  • Genprex, Inc. NCT ID

  • NCT04486833